Recurrent Ovarian Carcinoma
Showing NaN - NaN of 16
Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma
Active, not recruiting
- Recurrent Endometrial Endometrioid Adenocarcinoma
- +4 more
-
Anchorage, Alaska
- +584 more
Jan 28, 2023
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma Trial
Active, not recruiting
- Fallopian Tube Clear Cell Adenocarcinoma
- +14 more
- Cediranib
- +9 more
-
Birmingham, Alabama
- +399 more
Dec 30, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Active, not recruiting
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Ipilimumab
- Nivolumab
-
Auburn, California
- +205 more
Oct 18, 2022
Advanced Malignant Solid Tumor, Bladder Carcinoma, Breast Carcinoma Trial in Guam, Puerto Rico, United States (drug, procedure,
Recruiting
- Advanced Malignant Solid Neoplasm
- +49 more
- Adavosertib
- +36 more
-
Birmingham, Alabama
- +1429 more
Aug 17, 2022
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Bevacizumab
- +3 more
-
Phoenix, Arizona
- +44 more
Jan 10, 2022
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Completed
- Fallopian Tube Clear Cell Adenocarcinoma
- +17 more
- Elesclomol Sodium
- Paclitaxel
-
Phoenix, Arizona
- +162 more
Sep 28, 2021
Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Carcinoma Trial in Korea, Republic of, United States (Laboratory Biomarker
Completed
- Ovarian Clear Cell Adenocarcinoma
- Recurrent Ovarian Carcinoma
- Laboratory Biomarker Analysis
- Sunitinib Malate
-
Birmingham, Alabama
- +96 more
Feb 6, 2020
Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma
Completed
- Fallopian Tube Clear Cell Adenocarcinoma
- +19 more
- Bortezomib
- +3 more
-
Hartford, Connecticut
- +13 more
Aug 8, 2019
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Laboratory Biomarker Analysis
- +3 more
-
Mobile, Alabama
- +141 more
Jul 22, 2019
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma Trial in United
Completed
- Ovarian Clear Cell Cystadenocarcinoma
- +7 more
- Bevacizumab
- +4 more
-
Aurora, Colorado
- +12 more
Jul 19, 2019
Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma Trial in United
Completed
- Ovarian Clear Cell Cystadenocarcinoma
- +7 more
- Laboratory Biomarker Analysis
- +2 more
-
Birmingham, Alabama
- +6 more
Mar 8, 2019
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma Trial in Canada,
Completed
- Adult Hepatocellular Carcinoma
- +44 more
- Bevacizumab
- Temsirolimus
-
Scottsdale, Arizona
- +60 more
Jan 24, 2019
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma Trial in United States (Laboratory Biomarker
Completed
- Fallopian Tube Carcinoma
- +2 more
- Laboratory Biomarker Analysis
- PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1
-
Birmingham, Alabama
- +10 more
Dec 13, 2017
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma Trial in United States
Completed
- Recurrent Fallopian Tube Carcinoma
- +2 more
- Laboratory Biomarker Analysis
- Rilotumumab
-
Burbank, California
- +27 more
Aug 8, 2017
Collecting Tumor Samples From Patients With Gynecological Tumors
Completed
- Borderline Ovarian Clear Cell Tumor
- +85 more
- Laboratory Biomarker Analysis
-
Fayetteville, Arkansas
- +186 more
Oct 26, 2016
Fallopian Tube Carcinoma, Primary Peritoneal Carcinoma, Recurrent Ovarian Carcinoma Trial in United States (3-Dimensional
Completed
- Fallopian Tube Carcinoma
- +4 more
- 3-Dimensional Conformal Radiation Therapy
- +2 more
-
Chicago, Illinois
- +6 more
Feb 10, 2016